Valsamo Anagnostou
Overview
Explore the profile of Valsamo Anagnostou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
6541
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, et al.
Nature
. 2025 Feb;
639(8054):E19.
PMID: 40016449
No abstract available.
2.
Kelly R, Anagnostou V, Lam V, Zaidi A
Clin Transl Med
. 2025 Feb;
15(2):e70223.
PMID: 39902711
No abstract available.
3.
Rosner S, Connor S, Sanber K, Zahurak M, Zhang T, Gurumurthy I, et al.
Clin Cancer Res
. 2024 Nov;
31(2):339-351.
PMID: 39545922
Purpose: Co-mutations of the Kirsten rat sarcoma virus (KRAS) and serine/threonine kinase 11 (STK11) genes in advanced non-small cell lung cancer (NSCLC) are associated with immune checkpoint blockade (ICB) resistance....
4.
Shaikh F, Lee S, White J, Zhao Y, Ferri J, Pereira G, et al.
Cancers (Basel)
. 2024 Nov;
16(21).
PMID: 39518082
: Preclinical and clinical data indicate that chemoradiotherapy (CRT) in combination with checkpoint inhibitors may prime an anti-tumor immunological response in esophageal cancer. However, responses to neoadjuvant therapy can vary...
5.
Palmer T, Kessler M, Shao X, Balan A, Yarchoan M, Zaidi N, et al.
Cancer Res Commun
. 2024 Oct;
4(12):3137-3150.
PMID: 39470352
SpliceMutr shows that splicing antigenicity changes in response to ICI therapies and that native modulation of the splicing machinery through mutations increases the contribution of splicing to the neoantigen load...
6.
Fatteh M, Wehr J, Karaindrou K, Xian R, Gocke C, Lin M, et al.
JCO Precis Oncol
. 2024 Oct;
8:e2400254.
PMID: 39393037
Polyclonal convergent evolution to PARPi resistance in a patient with metastatic breast cancer with gPALB2.
7.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, et al.
Nature
. 2024 Oct;
635(8038):462-471.
PMID: 39385035
For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of...
8.
Kreimeyer K, Canzoniero J, Fatteh M, Anagnostou V, Botsis T
Stud Health Technol Inform
. 2024 Aug;
316:983-987.
PMID: 39176956
Modern generative artificial intelligence techniques like retrieval-augmented generation (RAG) may be applied in support of precision oncology treatment discussions. Experts routinely review published literature for evidence and recommendations of treatments...
9.
Botsis T, Spiker J, Kreimeyer K, Fatteh M, Wehr J, Najjar M, et al.
Stud Health Technol Inform
. 2024 Aug;
316:1854-1855.
PMID: 39176852
There is a critical need for a streamlined process to identify genotype-matched individuals eligible for enrollment into clinical trials and/or targeted therapies, as current methodologies face challenges in integrating diverse...
10.
Zemek R, Anagnostou V, Pires da Silva I, Long G, Lesterhuis W
Nat Rev Cancer
. 2024 Jun;
24(7):480-497.
PMID: 38886574
Many mechanisms underlying an effective immunotherapy-induced antitumour response are transient and critically time dependent. This is equally true for several immunological events in the tumour microenvironment induced by other cancer...